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Abstract
We conducted a retrospective cohort to examine the incidence and etiology of fever postinfluenza vaccination among hospitalized patients
during the 2015–2016 influenza season. Fever occurred in 63 (1.5%) of 4,185 vaccinated patients. Medical patients had fever predominantly
associated with concurrent infections; surgical patients had fever explained by noninfectious etiologies.
(Received 29 August 2018; accepted 9 November 2018; electronically published 7 December 2018)
Influenza vaccination is an important strategy for preventing
influenza infection and its sequelae. Traditionally, the rate of
influenza vaccination in hospitalized patients has been low, ran-
ging from 9.6% to 40.3%.1,2 This is partly due to provider con-
cerns regarding influenza vaccine safety and immunogenicity
among hospitalized patients with acute illnesses.3,4 There is also a
concern of postvaccination fever resulting in additional, unwar-
ranted diagnostic evaluations.2 The rate of postvaccination fever
in the adult outpatient population is low, ranging from 0.4%
to 1.5%.5,6
Several studies have found no evidence of increased vaccine-
associated adverse events in hospitalized surgical patients who
received influenza immunization.7,8 However, these studies asses-
sed only postdischarge fever. Data regarding the incidence and
causes of fever postinfluenza vaccination (PIV) among hospitalized
patients while still in the hospital are limited. Understanding PIV
fever is important for improving clinician acceptance of in-hospital
vaccination programs and compliance with government quality
measures for influenza vaccination.
Methods
We performed a retrospective cohort study at Barnes-Jewish
Hospital, a 1,250-bed teaching hospital, during the 2015–2016
influenza season. All patients aged≥ 18 years who received
influenza vaccination during their hospitalization were identified
by querying the medical informatics database. Postinfluenza
vaccination fever was defined as a recorded body temperature of
≥38.3°C within 48 hours after vaccination. Other collected data
included patient demographics, admission diagnosis, date and
time of vaccination and fever onset, any perioperative fever
<48 hours postprocedure, and any clinical laboratory evaluations
for infections (including blood cultures, urinalysis, urine culture,
and chest plain radiograph). A concomitant source of infection was
defined by a documented diagnosis of infection (subcategorized
into pulmonary, cardiovascular, gastrointestinal, genitourinary,
skin and soft tissue, bone and joint, primary bacteremia, and febrile
neutropenia) and whether the patient received a course of anti-
microbial therapy for≥ 4 days.
The causes of fever were classified into infectious and non-
infectious. Fever was attributed to infection when a concomitant
source of infection was present as defined above. Noninfectious
etiology of fever included benign postoperative fever, central
fever, vaccine-associated fever, and others. Benign postoperative
fever was defined as a fever <48 hours after surgery, without
clinical signs of infection, with negative infectious workup and/or
no antibiotic prescription.9 Central fever was classified as fever
occurring <72 hours of hospitalization in patients with subarachnoid
hemorrhage, intraventricular hemorrhage, or tumor and without
documented diagnosis of infection or sepsis syndrome. Vaccine-
associated fever was defined as fever <48 hours PIV without other
identifiable infectious and noninfectious (eg, acute pancreatitis,
myocardial infection) causes for fever.
During the study period, our institution administered Fluzone
quadrivalent (Sanofi Pasteur, Swiftwater, PA) and Fluzone high-dose
(Sanofi Pasteur, Swiftwater, PA) vaccine to patients aged 18–64 and≥65
years, respectively. All inpatients were screened for influenza vaccine
status by nurses and vaccinated if indicated and consent was obtained.
This procedure followed the Centers for Medicare and Medicaid Ser-
vices Influenza Immunization Core Measure (IMM-2).
Statistical analysis
Demographic and baseline characteristics were described in number
(percentage) for categorical variables and median (interquartile range,
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IQR) for continuous variables. We used χ2 and Mann-Whitney U tests
for comparisons where appropriate. All tests were 2-tailed, and a P
value of< .05 was considered statistically significant. The Washington
University Human Research Protection Office approved this study.
Results
Of 32,998 admissions, 96% were screened for influenza vaccination
status and 4,185 patients (12.7%) were vaccinated. Medical patients
received vaccination earlier in their hospital admission than surgical
patients: 13.0 hours (IQR, 5.2–27.8) versus 25.9 hours (IQR, 15.0–
165.2) (P= .001). Moreover, sixty-three vaccinated inpatients (1.5%)
experienced PIV fever. Among them, 28 (44.4%) and 35 (55.6%)
patients were admitted to medical and surgical services, respectively.
The median maximum temperature was significantly higher among
medical vs. surgical patients: 38.7°C (IQR, 38.4–39.3) versus 38.4°C
(IQR, 38.3–38.7) (P= .04). The mean time to fever after vaccination
was not different between the medical and surgical patients: 10.9 hours
(IQR, 5.4–27.3) versus 19.0 hours (IQR, 9.2–25.3) (P= .38). There was
no difference between the median length of stay between febrile and
nonfebrile patients postvaccination: 7 days versus 8 days (P= .58).
In the subgroup analysis of febrile surgical patients, 13 (37.1%) and
16 (45.7%) patients underwent elective and nonelective procedures
<48 hours after vaccination, respectively (Table 1). The remaining 6
patients (17.1%) did not have surgery. Compared with the nonelective
procedure subgroup, patients who had elective surgery were more likely
to develop perioperative fever within 48 hours PIV (P= .01). Never-
theless, there was no significant difference in the proportion of patients
who underwent an infectious investigation between the 2 subgroups
(P= .11). None of the investigations were positive for an infectious
etiology (Table 1). The nonelective subgroup tended to have a higher
length of hospital stay than the elective surgical patients (P= .02).
In total, 21 (75%) medical patients had fever attributable to con-
comitant infections (Table 2). Most of the surgical patients (76.9%) who
underwent elective procedure had fever potentially explained by benign
postoperative fever, while 10 (62.5%) cases in the nonelective surgical
subgroup had fever more likely caused by concomitant infection.
Overall, medical patients had fever predominantly caused by infections,
while surgical patients had febrile illness explained by noninfectious
etiologies (P= .03). None of the patients with noninfectious fever PIV
were started on antibiotics within 48 hours of their fever.






(n= 16) P Value
No. of patients who received influenza vaccination
∙ Prior to the surgical procedure, no. (%) 3 (23.1) 8 (50) .14
∙ After the surgical procedure, no. (%) 10 (76.9) 8 (50)
Fever within 48 h of vaccination, no. (%) 12 (92.3) 7 (43.6) .01
Maximum temperature (°C), median (IQR) 38.5 (38.4–38.7) 38.4 (38.3–38.7) .53
Time of vaccination to fever postvaccination, median (IQR) 11.1 (6.3–25.6) 19.1 (4.6–24.9) .78
Infectious investigations, no. (%)b 6 (46.1) 3 (18.6) .11
∙ Positive for infection, no. 0 0
∙ Negative for infection, no. 6 3
Length of stay, median (IQR) 5.0 (3.0–7.5) 14.5 (6.0–29.3) .02
a6 surgical patients did not undergo any procedure.
bInfectious investigation was defined as obtaining one or more of the following within 48 hours of fever onset: blood cultures, urinalysis, urine cultures and/or chest X-ray.
Table 2. Causes of Fever Following Influenza Vaccination in the Hospitalized
Medicine and Surgical Patients













Pulmonary 4 0 1 2
Cardiovascular 0 0 1 1
Gastrointestinal 3 0 4 1
Genitourinary 5 0 2 0
Skin and soft
tissue infection
2 1 2 1
Bone and joint 3 0 0 0
Bloodstream
infection
6 0 0 1
Febrile
neutropenia
2 0 0 0
Noninfectious
causes
Postsurgical fever 0 10 3 0
Central fever 1 2 3 0
Postvaccination
fever
1 0 0 0
Othersb 5 0 0 0
aSome patients could have 2 or more infectious processes.
bOthers include acute pancreatitis or myocardial infection.
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Discussion
Fever PIV is a recognized adverse event, but the rate remains low
in both outpatient and inpatient settings.5–8 In our cohort, the
incidence of fever PIV during hospitalization was 1.5%, which is
consistent with a previously published range of 1.5%–2.0%.7,8
A prospective study found similar self-reported fever PIV among
hospitalized (2%) and clinic patients (2%).7 Tartof et al8 reported
that 1.5% of hospitalized surgical patients had a postdischarge
fever following vaccination, versus 1.1% of unvaccinated patients.
It is often assumed that a fever PIV is generally due to vaccination
itself. However, no studies have investigated the etiologies of fever PIV.
Kohl et al10 suggested evaluating patients with fever PIV for alternative
explanations. Most febrile episodes in our cohort were attributable to
concomitant infections, benign postoperative fever, or central fever.
Only 1 medical patient had a postvaccination fever without an
alternative explanation. Fever due to infection was more common
among medical patients; 75% of these patients in our cohort were
admitted because of an infection.
Although elective surgical patients were more likely to develop
perioperative fever within 48 hours PIV compared with nonelective
surgical subgroup, there was no increase in the proportion
undergoing additional evaluation for infection. Our finding is
consistent with a previous study.8 The length of hospital stay was
longer in the nonelective surgical subgroup, which was more likely
due to the complexity of their underlying medical conditions.
The limitations of our study include retrospective analysis in a
single institution, with a single vaccine manufacturer during a
single influenza season. Therefore, our findings may not be
generalizable to other populations. Because our data only inclu-
ded fever within the first 48 hours postvaccination, we may have
missed patients who developed fever after 48 hours.
This is the first study examining the incidence and etiologies of
fever within 48 hours PIV among an inpatient population. Our
data suggest that incidence of fever PIV in hospitalized patients
was low and was primarily caused by concurrent infectious pro-
cesses and other noninfectious causes rather than influenza vac-
cination itself.
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